ArticleEuropean journal of nuclear medicine and molecular imaging2017
Radiolabeled pertuzumab for imaging of human epidermal growth factor receptor 2 expression in ovarian cancer.
Article in European journal of nuclear medicine and molecular imaging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 35 citations in OpenAlex.
- Dual-receptor PET imaging of ovarian cancer using aAmerican journal of nuclear medicine and molecular imaging · 2025Article
- Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- Immunotherapeutic Approaches in Ovarian Cancer.Current issues in molecular biology · 2023Review
- Dive into the details of radionuclide antibody conjugates: what role do EPR effects and LETs of different radionuclides play?American journal of nuclear medicine and molecular imaging · 2023Article
- Advances in aptamer-based nuclear imaging.European journal of nuclear medicine and molecular imaging · 2022Review
- Radiolabeled Antibodies for Cancer Imaging and Therapy.Cancers · 2022Review
- ImmunoPET: Antibody-Based PET Imaging in Solid Tumors.Frontiers in medicine · 2022Review
- Advances in the Application of Radionuclide-Labeled HER2 Affibody for the Diagnosis and Treatment of Ovarian Cancer.Frontiers in oncology · 2022Review
- Review: Radionuclide Molecular Imaging Targeting HER2 in Breast Cancer with a Focus on Molecular Probes into Clinical Trials and Small Peptides.Molecules (Basel, Switzerland) · 2021Review
- Next-Generation Molecular Imaging of Thyroid Cancer.Cancers · 2021Review
- HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging.European journal of nuclear medicine and molecular imaging · 2021Review
- PET and SPECT Imaging of the EGFR Family (RTK Class I) in Oncology.International journal of molecular sciences · 2021Review
- Virus-Mimicking Nanoparticles for Targeted Near Infrared Fluorescence Imaging of Intraperitoneal Ovarian Tumors in Mice.Annals of biomedical engineering · 2021Article
- Evaluation of Liquid Biopsy in Patients with HER2-Positive Breast Cancer.BioMed research international · 2021Article
- ImmunoPET: Concept, Design, and Applications.Chemical reviews · 2020Review
- Imaging of Preclinical Endometrial Cancer Models for Monitoring Tumor Progression and Response to Targeted Therapy.Cancers · 2019Review
- ImmunoPET imaging of CD38 expression in hepatocellular carcinoma usingAmerican journal of translational research · 2019Article
- Ovarian Cancer Targeted Theranostics.Frontiers in oncology · 2019Review
- Dual-labeled pertuzumab for multimodality image-guided ovarian tumor resection.American journal of cancer research · 2019Article
- HER2-targeted multimodal imaging of anaplastic thyroid cancer.American journal of cancer research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 3 countries.
Funding
Abstract
purposeHuman epidermal growth factor receptor 2 (HER2) is over-expressed in over 30% of ovarian cancer cases, playing an essential role in tumorigenesis and metastasis. Non-invasive imaging of HER2 is of great interest for physicians as a mean to better detect and monitor the progression of ovarian cancer. In this study, HER2 was assessed as a biomarker for ovarian cancer imaging using
methodsHER2 expression and binding were examined in three ovarian cancer cell lines (SKOV3, OVCAR3, Caov3) using in vitro techniques, including western blot and saturation binding assays. PET imaging and biodistribution studies in subcutaneous models of ovarian cancer were performed for non-invasive in vivo evaluation of HER2 expression. Additionally, orthotopic models were employed to further validate the imaging capability of
resultsHER2 expression was highest in SKOV3 cells, while OVCAR3 and Caov3 displayed lower HER2 expression.
conclusions
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.